<?xml version='1.0' encoding='utf-8'?>
<document id="28167510"><sentence text="Preclinical Development of a Nontoxic Oral Formulation of Monoethanolamine, a Lipid Precursor, for Prostate Cancer Treatment."><entity charOffset="58-74" id="DDI-PubMed.28167510.s1.e0" text="Monoethanolamine" /></sentence><sentence text="Purpose: Most currently available chemotherapeutic agents target rampant cell division in cancer cells, thereby affecting rapidly dividing normal cells resulting in toxic side-effects" /><sentence text=" This nonspecificity necessitates identification of novel cellular pathways that are reprogrammed selectively in cancer cells and can be exploited to develop pharmacologically superior and less toxic therapeutics" /><sentence text=" Despite growing awareness on dysregulation of lipid metabolism in cancer cells, targeting lipid biosynthesis is still largely uncharted territory" /><sentence text=" Herein, we report development of a novel nontoxic orally deliverable anticancer formulation of monoethanolamine (Etn) for prostate cancer by targeting the Kennedy pathway of phosphatidylethanolamine (PE) lipid biosynthesis"><entity charOffset="96-112" id="DDI-PubMed.28167510.s5.e0" text="monoethanolamine" /><entity charOffset="175-199" id="DDI-PubMed.28167510.s5.e1" text="phosphatidylethanolamine" /><entity charOffset="201-203" id="DDI-PubMed.28167510.s5.e2" text="PE" /><pair ddi="false" e1="DDI-PubMed.28167510.s5.e0" e2="DDI-PubMed.28167510.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28167510.s5.e0" e2="DDI-PubMed.28167510.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28167510.s5.e0" e2="DDI-PubMed.28167510.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28167510.s5.e1" e2="DDI-PubMed.28167510.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28167510.s5.e1" e2="DDI-PubMed.28167510.s5.e2" /></sentence><sentence text="Experimental Design: We first evaluated gastrointestinal tract stability, drug-drug interaction liability, pharmacokinetic, and toxicokinetic properties of Etn to evaluate its suitability as a nontoxic orally deliverable agent" /><sentence text=" We next performed in vitro and in vivo experiments to investigate efficacy and mechanism of action" /><sentence text="Results: Our data demonstrate that Etn exhibits excellent bioavailability, gastrointestinal tract stability, and no drug-drug interaction liability" /><sentence text=" Remarkably, orally fed Etn inhibited tumor growth in four weeks by approximately 67% in mice bearing human prostate cancer PC-3 xenografts without any apparent toxicity" /><sentence text=" Mechanistically, Etn exploits selective overexpression of choline kinase in cancer cells, resulting in accumulation of phosphoethanolamine (PhosE), accompanied by downregulation of HIF-1α that induces metabolic stress culminating into cell death"><entity charOffset="59-66" id="DDI-PubMed.28167510.s10.e0" text="choline" /><entity charOffset="120-139" id="DDI-PubMed.28167510.s10.e1" text="phosphoethanolamine" /><pair ddi="false" e1="DDI-PubMed.28167510.s10.e0" e2="DDI-PubMed.28167510.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28167510.s10.e0" e2="DDI-PubMed.28167510.s10.e1" /></sentence><sentence text="Conclusions: Our study provides first evidence for the superior anticancer activity of Etn, a simple lipid precursor formulation, whose nontoxicity conforms to FDA-approved standards, compelling its clinical development for prostate cancer management" /><sentence text=" Clin Cancer Res; 23(14); 3781-93" /><sentence text=" ©2017 AACR" /><sentence text="" /></document>